<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Excretion of <z:chebi fb="2" ids="18095">hydroxyproline</z:chebi> with urine was studied in 16 children (5-14 years old) with Marphan-Like syndrome and Marphan, Ehlers-Dunlos and Larson syndromes after therapy involving <z:chebi fb="2" ids="8499">propranolol</z:chebi> and a complex of vitamins (<z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi>, <z:chebi fb="12" ids="17015">riboflavin</z:chebi> and <z:chebi fb="5" ids="16709">pyridoxine</z:chebi>) and recommended on the basis of echocardiographic analyses </plain></SENT>
<SENT sid="1" pm="."><plain>The therapeutic course appears to cause quantitative and qualitative correction of collagen and apparently of elastin fibrilles development </plain></SENT>
<SENT sid="2" pm="."><plain>Depending on initial patterns of <z:chebi fb="2" ids="18095">hydroxyproline</z:chebi> excretion and the syndrome form the correction could be complete or partial, while positive effect of the treatment was stable or provisional </plain></SENT>
<SENT sid="3" pm="."><plain>The data obtained suggest that the complex treatment developed might be applied as a preoperative therapy of the patients with Marphan-like syndrome as well as with syndromes of Marphan and Ehlers-Dunlos before thoracoplastics caused by hereditary chest deformation and by impairments of cardiovascular system </plain></SENT>
</text></document>